Abstract
Central nervous system (CNS) selective amino acid transporters provide an important function in maintaining tonic extracellular levels of amino acids that act as neurotransmitters, synaptic modulators or neurotransmitter precursors. Small molecule inhibitors of these transporters have been postulated and in some cases demonstrated to be useful in the treatment of a range of CNS driven disorders such as epilepsy, anxiety, psychosis, depre-ssion, pain and neurodegenerative disease. Although much of the research to date in this field has focussed on inhibition of the g -amino butyric acid (GABA) transporters more recent reports have also generated interest in modulation of glycine, glutamate and proline transporters. This article will review the current medicinal chemistry literature and structure activity relationships known for mammalian CNS selective amino acid transporters.
Keywords: inhibitors, mammalian central nervous system, amino butyric acid GABA transporters, GAT1, Glycine transporter, proline transporter, taurine transporter, cationic amino acid transporters, glutamate transporters
Current Medicinal Chemistry
Title: Inhibitors of Mammalian Central Nervous System Selective Amino Acid Transporters
Volume: 7 Issue: 2
Author(s): Richard E. Armer
Affiliation:
Keywords: inhibitors, mammalian central nervous system, amino butyric acid GABA transporters, GAT1, Glycine transporter, proline transporter, taurine transporter, cationic amino acid transporters, glutamate transporters
Abstract: Central nervous system (CNS) selective amino acid transporters provide an important function in maintaining tonic extracellular levels of amino acids that act as neurotransmitters, synaptic modulators or neurotransmitter precursors. Small molecule inhibitors of these transporters have been postulated and in some cases demonstrated to be useful in the treatment of a range of CNS driven disorders such as epilepsy, anxiety, psychosis, depre-ssion, pain and neurodegenerative disease. Although much of the research to date in this field has focussed on inhibition of the g -amino butyric acid (GABA) transporters more recent reports have also generated interest in modulation of glycine, glutamate and proline transporters. This article will review the current medicinal chemistry literature and structure activity relationships known for mammalian CNS selective amino acid transporters.
Export Options
About this article
Cite this article as:
Armer E. Richard, Inhibitors of Mammalian Central Nervous System Selective Amino Acid Transporters, Current Medicinal Chemistry 2000; 7 (2) . https://dx.doi.org/10.2174/0929867003375380
DOI https://dx.doi.org/10.2174/0929867003375380 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design An Overview of Galenic Preparation Methods for Medicinal Cannabis
Current Bioactive Compounds 5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Classification of Normal and Epileptic EEG Signals Using Adaptive Neuro-Fuzzy Network Based on Time Series Prediction
Neuroscience and Biomedical Engineering (Discontinued) Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies
Current Medicinal Chemistry Tactile Angle Discrimination Decreases due to Subjective Cognitive Decline in Alzheimer’s Disease
Current Alzheimer Research Autonomic Nervous System Alterations in Rett Syndrome
Current Pediatric Reviews Preparation, Characterization and in vivo Evaluation of Simple Monolithic Ethylcellulose-coated Pellets Containing Topiramate with Biphasic Release Characteristics
Current Drug Delivery One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Development of Allosteric Modulators of Voltage-Gated Na<sup>+</sup> Channels: A Novel Approach for an Old Target
Current Topics in Medicinal Chemistry The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia
Current Pharmaceutical Design Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611)
CNS & Neurological Disorders - Drug Targets Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Rational Drug Design and the Discovery of the Δ2-1,2,3-Triazolines, A Unique Class of Anticonvulsant and Antiischemic Agents
Current Medicinal Chemistry